Press releaseGlobe Newswire
Radiopharm Theranostics
RADX · ASX
$1.01+$0.06 (+6.32%)TodayMarket closed ·
Prev close $0.95
Latest news
- News
12 Health Care Stocks Moving In Monday's After-Market Session
- News
12 Health Care Stocks Moving In Thursday's Pre-Market Session
- News
12 Health Care Stocks Moving In Monday's Pre-Market Session
- News
Radiopharm Theranostics Schedules An FDA End-Of-Phase 2 For October 1, 2026, To Align On The Design Of A Pivotal Phase 3 Trial To Evaluate RAD101 In Patients With Suspected Recurrence Of Brain Metastases Following Radiotherapy
- Press releaseGlobe Newswire
Radiopharm Theranostics To Meet with U.S. FDA to Align on Pivotal Phase 3 Trial Design for RAD 101 in Diagnosis of Brain Metastases
- News
12 Health Care Stocks Moving In Friday's After-Market Session
- News
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
- News
12 Health Care Stocks Moving In Monday's After-Market Session
- News
12 Health Care Stocks Moving In Friday's Intraday Session
- NewsAvi Kapoor
US Stocks Mixed; American Express Shares Fall Following Q2 Results
- News
12 Health Care Stocks Moving In Friday's Pre-Market Session
- Press releaseGlobe Newswire
Radiopharm Theranostics Announces Concurrent US$4.1 Million Registered Direct Offering and Up To Additional A$12.7 (US$8.9) Million Australian Placement and Share Purchase Plan
- Press releaseGlobe Newswire
A Cancer Antigen Long Thought Untouchable Is Suddenly the Hottest Target in Oncology
- Press releaseGlobe Newswire
Radiopharm Theranostics Completes Enrollment in U.S. Phase 2b Imaging Trial of RAD 101 for Diagnosis of Brain Metastases
- News
12 Health Care Stocks Moving In Thursday's After-Market Session
- News
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
- NewsVandana Singh
Radiopharm Theranostics Eyes Pivotal Trial Path After Encouraging Interim Results
- Press releaseGlobe Newswire
Radiopharm Theranostics Reports Half-Year Financial Results and Business Updates
- News
12 Health Care Stocks Moving In Monday's After-Market Session
- News
Benzinga Bulls And Bears: Carnival, Caterpillar, Meta — And Markets Make Modest Gains
- NewsVandana Singh
Why Is Radiopharm Theranostics Stock Rallying Over 140%?
- News
Market-Moving News for December 15th
- Press releaseGlobe Newswire
Radiopharm Theranostics Receives Approval to Initiate Phase 1 Therapeutic Trial of RAD 402 (KLK3-mAb with Tb161) in Advanced Prostate Cancer
- News
Australia's Agency Has Approved Radiopharm Theranostics' First-in-human Phase 1 Trial Of Rad 402, For Metastatic Or Locally Advanced Prostate Cancer-6K
- Press releaseGlobe Newswire
Radiopharm Theranostics completes A$35 million Placement and launches a A$5 million Share Purchase Plan
- News
12 Health Care Stocks Moving In Wednesday's Intraday Session
- News
12 Health Care Stocks Moving In Friday's After-Market Session
- News
12 Health Care Stocks Moving In Monday's After-Market Session
- NewsAvi Kapoor
Top 3 Health Care Stocks You'll Regret Missing This Month
- NewsAvi Kapoor
Royal Caribbean Cruises Posts Upbeat Earnings, Joins Brighthouse Financial, Invesco, Boeing And Other Big Stocks Moving Higher On Tuesday
- NewsAvi Kapoor
Cytek Biosciences, Emergent BioSolutions, Radiopharm Theranostics And Other Big Stocks Moving Higher On Monday
- NewsAvi Kapoor
Why C3.ai Shares Are Trading Higher By Around 8%; Here Are 20 Stocks Moving Premarket
- NewsAvi Kapoor
Nasdaq Down Over 100 Points; US Wholesale Inventories Rise By 0.2%
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.